Nuclear, compared with combined nuclear and cytoplasmic expression of maspin, is linked in lung adenocarcinoma to reduced VEGF-A levels and in Stage I, improved survival

Histopathology

Volumn 54, Issue 5, 2009, Pages 590-597

  Frey, Amy ^a   Soubani, Ayman O ^b   Adam, Abdulgadir K ^b   Sheng, Shijie ^a   Pass, Harvey I ^c   Lonardo, Fulvio ^a,d  

^a Departments of Pathology   (United States)

^b WAYNE STATE UNIVERSITY   (United States)

^c NEW YORK UNIVERSITY   (United States)

^d HARPER UNIVERSITY HOSPITAL   (United States)

Author keywords

Lung adenocarcinoma; Maspin; P53; Prognosis; Stage I; Subcellular localization; VEGF A

Indexed keywords

MASPIN; PROTEIN P53; VASCULOTROPIN A;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CELL NUCLEUS MEMBRANE; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CLINICAL FEATURE; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOPLASM; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; LUNG RESECTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RETROSPECTIVE STUDY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CELL NUCLEUS; CYTOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIERS ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; SERPINS; TISSUE ARRAY ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 64549119748     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2009.03260.x     Document Type: Article

References (35)

1. Bailey CM, Khalkhali-Elllis Z, Seftor EA, Hendrix MJ. Biological functions of maspin. J. Cell. Physiol. 2006 209 617 624.
2. Sheng S. A role of novel serpin maspin in tumor progression: the divergence revealed through efforts to converge. J. Cell. Physiol. 2006 209 631 635.
3. Khalkhali-Ellis Z. Maspin, the new frontier. Clin. Cancer Res. 2006 12 7279 7283.
4. Czerwenka KF, Manavi M, Hosmann J et al. Comparative analysis of two-dimensional protein patterns in malignant and normal human breast tissue. Cancer Detect. Prev. 2001 25 268 279.
5. Maass N, Hojo T, Rosel F, Ikeda T, Jonat W, Nagasaki K. Down regulation of the tumor suppressor gene maspin in breast carcinoma is associated with a higher risk of distant metastasis. Clin. Biochem. 2001 34 303 307.
6. Maass N, Teffner M, Rosei F et al. Decline in the expression of the serine proteinase inhibitor maspin is associated with tumour progression in ductal carcinomas of the breast. J. Pathol. 2001 195 321 326.
7. Zou Z, Anisowicz A, Hendrix MJ et al. Maspin, a serpin with tumor-suppressing activity in human mammary epithelial cells. Science 1994 263 526 529.
8. Bieche I, Girault I, Sabourin JC et al. Prognostic value of maspin mRNA expression in ER alpha-positive postmenopausal breast carcinomas. Br. J. Cancer 2003 88 863 870.
9. Stathopoulou A, Mavroudis D, Perraki M et al. Molecular detection of cancer cells in the peripheral blood of patients with breast cancer: comparison of CK-19, CEA and maspin as detection markers. Anticancer Res. 2003 23 1883 1890.
10. Umekita Y, Ohi Y, Sagara Y, Yoshida H. Expression of maspin predicts poor prognosis in breast-cancer patients. Int. J. Cancer 2002 100 452 455.
11. Umekita Y, Yoshida H. Expression of maspin is up-regulated during the progression of mammary ductal carcinoma. Histopathology 2003 42 541 545.
12. Mohsin SK, Zhang M, Clark GM, Craig Allred D. Maspin expression in invasive breast cancer: association with other prognostic factors. J. Pathol. 2003 199 432 435.
13. Sood AK, Fletcher MS, Gruman LM et al. The paradoxical expression of maspin in ovarian carcinoma. Clin. Cancer Res. 2002 8 2924 2932.
14. Solomon LA, Munkarah AR, Schimp VL et al. Maspin expression and localization impact on angiogenesis and prognosis in ovarian cancer. Gynecol. Oncol. 2006 101 385 389.
15. Langenfeld J, Lonardo F, Kiyokawa H et al. Inhibited transformation of immortalized human bronchial epithelial cells by retinoic acid is linked to cyclin E down-regulation. Oncogene 1996 13 1983 1990.
16. Lonardo F, Dragnev KH, Freemantle SJ et al. Evidence for the epidermal growth factor receptor as a target for lung cancer prevention. Clin. Cancer Res. 2002 8 54 60.
17. Lonardo F, Rusch V, Langenfeld J, Dmitrovsky E, Klimstra DS. Overexpression of cyclins D1 and E is frequent in bronchial preneoplasia and precedes squamous cell carcinoma development. Cancer Res. 1999 59 2470 2476.
18. Siddiq F, Sarker FH, Wali A, Pass HI, Lonardo F. Increased osteonectin expression is associated with malignant transformation and tumor associated fibrosis in the lung. Lung Cancer 2004 45 197 205.
19. Lonardo F, Li X, Siddiq F et al. Maspin nuclear localization is linked to favorable morphological features in pulmonary adenocarcinoma. Lung Cancer 2006 51 31 39.
20. Smith SL, Watson SG, Ratschiller D, Gugger M, Betticher DC, Heighway J. Maspin - the most commonly-expressed gene of the 18q21.3 serpin cluster in lung cancer - is strongly expressed in preneoplastic bronchial lesions. Oncogene 2003 22 8677 8687.
21. Woenckhaus M, Bubendorf L, Dalquen P et al. Nuclear and cytoplasmic Maspin expression in primary non-small cell lung cancer. J. Clin. Pathol. 2007 60 483 486.
22. Nakashima M, Ohike N, Nagasaki K, Adachi M, Morohoshi T. Prognostic significance of the maspin tumor suppressor gene in pulmonary adenocarcinoma. J. Cancer Res. Clin. Oncol. 2004 130 475 479.
23. Hirai K, Koizumi K, Haraguchi S et al. Prognostic significance of the tumor suppressor gene maspin in non-small cell lung cancer. Ann. Thorac. Surg. 2005 79 248 253.
24. Katakura H, Takenaka K, Nakagawa M et al. Maspin gene expression is a significant prognostic factor in resected non-small cell lung cancer (NSCLC). Maspin in NSCLC. Lung Cancer 2006 51 323 328.
25. Nakagawa M, Katakura H, Adachi M et al. Maspin expression and its clinical significance in non-small cell lung cancer. Ann. Surg. Oncol. 2006 13 1517 1523.
26. Mineo TC, Ambrogi V, Baddi A et al. Prognostic impact of VEGF, CD31, CD34, and CD105 expression and tumour vessel invasion after radical surgery for IB-IIA non-small cell lung cancer. J. Clin. Pathol. 2004 57 591 597.
27. Han H, Siverman JF, Santucci TS et al. Vascular endothelial growth factor expression in stage I non-small cell lung cancer correlates with neoangiogenesis and a poor prognosis. Ann. Surg. Oncol. 2001 8 72 79.
28. Ohta Y, Tanaka Y, Watanabe G, Minato H. Predicting recurrence following curative surgery in stage I non-small cell lung cancer patients using an angiogenesis-associated factor. J. Exp. Clin. Cancer Res. 2007 26 301 305.
29. Stinchcombe TE, Socinski MA. Bevacizumab in the treatment of non-small-cell lung cancer. Oncogene 2007 26 3691 3698.
30. Cho JH, Kim HS, Park CS et al. Maspin expression in early oral tongue cancer and its relation to expression of mutant-type p53 and vascular endothelial growth factor (VEGF). Oral Oncol. 2007 43 272 277.
31. Li JJ, Chen Y, Zhang SM et al. Pathobiological significance of vascular endothelial growth factor and Maspin expressions in human gastric carcinoma. World J. Gastroenterol. 2004 10 2624 2627.
32. Schedel J, Distler O, Woenckhaus M et al. Discrepancy between mRNA and protein expression of tumour suppressor maspin in synovial tissue may contribute to synovial hyperplasia in rheumatoid arthritis. Ann. Rheum. Dis. 2004 63 1205 1211.
33. Fabbro M, Henderson BR. Regulation of tumor suppressors by nuclear-cytoplasmic shuttling. Exp. Cell Res. 2003 282 59 69.
34. Wang SC, Hung MC. Cytoplasmic/nuclear shuttling and tumor progression. Ann. NY Acad. Sci. 2005 1059 11 15.
35. Hervy M, Hoffman L, Beckerle MC et al. From the membrane to the nucleus and back again: bifunctional focal adhesion proteins. Curr. Opin. Cell Biol. 2006 18 524 532.